DAPT De Escalation Strategy Calculator Ticagrelor or Prasugrel to Clopidogrel

Clinical calculation support · Verify results before clinical use

Clinical decision inputs

Enter the patient's post-PCI status to organize factors relevant to P2Y12 inhibitor de-escalation.

Clinical aid · Not a validated score

Enter elapsed time from the index PCI. Routine de-escalation during the first month is generally discouraged.

High bleeding risk: at least 1 major or 2 minor ARC-HBR criteria.

Examples include clinically important gastrointestinal bleeding or intolerable ticagrelor-related dyspnoea.

Examples: left main PCI, long total stent length, multiple stents, two-stent bifurcation PCI, or prior stent thrombosis.

Clinical context

For patients with ACS undergoing PCI, aspirin plus an oral P2Y12 inhibitor is the default antiplatelet strategy for 12 months when bleeding risk is not high. Ticagrelor or prasugrel is generally preferred to clopidogrel in ACS patients undergoing PCI when suitable. The 2025 ACC/AHA ACS guideline states that switching from ticagrelor or prasugrel to clopidogrel after 1 month may be reasonable in selected patients to reduce bleeding risk.

Evidence for de-escalation comes from trials with specific populations and protocols. TALOS-AMI studied stabilized patients with myocardial infarction who had no major ischemic or bleeding events during the first month after PCI; TROPICAL-ACS evaluated a platelet-function-guided step-down strategy from prasugrel. These findings should not be generalized automatically to every patient, every P2Y12 inhibitor, or unstable patients.

How to use this tool

  • Use it to organize a clinical review, not to prescribe, switch, or interrupt antiplatelet treatment automatically.
  • Assess bleeding and ischemic risk, clinical stability, adherence, coronary anatomy, comorbidities, drug interactions, and patient preferences.
  • For patients receiving oral anticoagulation, review the entire antithrombotic regimen and aspirin duration separately.
  • Major bleeding, recurrent ischemia, or suspected stent thrombosis requires prompt clinical assessment.

References

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
J Am Coll Cardiol. DOI: 10.1016/j.jacc.2024.11.009
Kim CJ, et al. TALOS-AMI: Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing PCI.
Lancet. 2021;398:1305-1316. PMID: 34627490. DOI: 10.1016/S0140-6736(21)01445-8
Sibbing D, et al. TROPICAL-ACS: Guided de-escalation of antiplatelet treatment in patients with ACS undergoing PCI.
Lancet. 2017;390:1747-1757. PMID: 28855078. DOI: 10.1016/S0140-6736(17)32155-4
Clinical disclaimer: This tool is intended for healthcare professionals as a decision-support aid. It does not replace current guidelines, individualized clinical judgment, or local protocols. Do not stop, switch, or alter antiplatelet therapy solely on the basis of this output. The custom driver tallies have not been prospectively validated.